Skip to main content
OpenTrials
Completed

NCT Number: NCT06597370

Immunogenicity Induced by COVID-19 Vaccines in Mexican Population

To determine the gene expression of anti-spike IgG through PCR-RT in patients vaccinated with the 4 types of vaccines available in Mexico Oxford/AstraZeneca (ChAdOx1 nCoV-19), Centro Nacional Gamaleya (Sputnik V), Pfizer/BioNTech (BNT162b2) and Sinovac (CoronaVac).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Vaccine

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Escuela Superior de Medicina, Instituto Politécnico Nacional

Mexico City, 11340, Mexico

About this study

80 subjects with full vaccination schedule will be included, 20 per group To know the gene expression of IgG anti-spike through PCR-RT in patients vaccinated with the 4 types of vaccines available in Mexico Oxford/AstraZeneca (ChAdOx1 nCoV-19), Centro Nacional Gamaleya (Sputnik V), Pfizer/BioNTech (BNT162b2) and Sinovac (CoronaVac).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • - Mexican people.
  • - Over 18 years of age.
  • - With complete vaccination schedule against COVID-19.
  • - Allowing peripheral blood samples to be taken.
  • - To sign an informed consent form.
  • - To agree to participate in the protocol.

Exclusion criteria

  • - Persons with incomplete vaccination schedule against COVID-19.
  • - Persons who have 30 +/- 5 days of having completed the vaccination scheme against COVID-19.
  • - People under treatment with any immunosuppressive drug.
  • People who refuse to sign the informed consent form.

Treatment and study plan

Gene expression mRNA of IgG anti-spike

Other

b) Peripheral venous blood samples (3 ml per occasion) will be taken from all participants. They will be carried out on days 30,60 and 120 after completion of the COVID-19 vaccination schedule.

c) Sample processing:

  • tRNA extraction from all samples.
  • cDNA synthesis
  • Real time PCR performance.

Primary outcomes

  1. Immunogenicity induced by COVID-19 vaccines in Mexican population

    Time frame: 4 months

    To characterize the immunogenicity induced by COVID-19 vaccines in Mexican population: mRNA expression for IgG anti-spike.

Sponsors and collaborators

Lead sponsor

National Polytechnic Institute, Mexico

Other

Registry information

Official study title

Immunogenicity Induced by COVID-19 Vaccines in Mexican Population: mRNA Expression for IgG Anti-spike

Acronym: Vaccines COVID

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Sep 19, 2024
Registry last updated
Oct 4, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.